Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the contex tof Tivozanib & Renal Cell Carcinoma (RCC), tivozanib is approved in both the US (FDA) and EU (EMA) for Renal Cell Carcinoma (RCC), with the FDA approval restricted to later‑line, relapsed/refractory disease after ≥2 prior systemic therapies, whereas the EMA authorizes it more broadly in first‑line and certain VEGFR‑inhibitor‑naïve settings (1, 2, 4)
In cases of relapsed, refractory renal cell carcinoma (RCC), tivozanib can be considered as a treatment option in the later stages, particularly after the disease has progr…